ClinicalTrials.gg
CompletedNCT01474161Updated Nov 27, 2012

Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505

A Phase 1 interventional study of GFT505 120mg - old formulation and GFT505 120mg - new formulation in Type 2 Diabetes, Diabetes Mellitus, Type 2 and Metabolic Diseases, sponsored by Genfit. Completed at 1 site in France. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-11-27.

Sponsored by Genfit · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 414 studies in Diabetes Mellitus, Type 2 with a site in France — 36 open to participants now, 41 under way, 9 of them phase 3. Diabetes Mellitus, Type 2 · France.

Enrollment
227th of 336
96 · median 312
Started
2011
with 23 others
Phase 1
6 of 414
none open now
Registered
169th of 414
by date

Among the 414 studies in Diabetes Mellitus, Type 2 with a site in France, this one is the 227th largest by enrollment of the 336 interventional ones that give a count, is one of 24 that started in 2011, is one of 6 in phase 1, and was the 169th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

36 of the 414 studies in Diabetes Mellitus, Type 2 with a site in France are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 414 studies in Diabetes Mellitus, Type 2 with a site in France, or all of them as a file.
02

Study summary

The Sponsor, Genfit, has developed a new formulation of GFT505 (60 mg). The objective is to compare the relative bioavailability between the new GFT505 formulation (capsule dosed at 60 mg GFT505) and the old GFT505 formulation (capsule dosed at 20 mg GFT505) in healthy male subjects and to assess the impact of gender on this relative bioavailability after administration in male and female subjects.

Using the new formulation, a single and a multiple ascending dose study will be performed in overweight or obese male subjects otherwise healthy whose demographic and physiological characteristics are thought to be closer to those of the target population (Type 2 diabetes). Thereafter, a group of male and female patients with Type 2 diabetes will receive multiple dose administration of GFT505.

Read the detailed description

The study will be divided in 4 successive parts :

  • Study Part I will be a comparative bioavailability between a new GFT505 formulation (capsule dosed at 60 mg GFT505 by capsule) and the old GFT505 formulation (capsule dosed at 20 mg GFT505 by capsule) coupled with an evaluation of the gender effect assessed with the new formulation. In this purpose a group of 12 male subjects will receive successively both formulations on a unique occasion in a randomized manner while a group of 12 female subjects will receive the new formulation on one occasion only. This part of the study will be done in healthy volunteers.
  • Study Part II will be a single ascending dose to be run at a maximum of 3 dose levels. Subjects included in this part of the study will receive only one dose level to limit the exposure to GFT505. Three cohorts of 8 subjects are planned to be included. This part will be run in overweight or obese subjects.
  • Study Part III will start after completion of the first Cohort of Study Part II. Study Part III will be a multiple ascending dose to be run at a maximum of 3 dose levels. Subjects included in this part of the study will receive only one dose level to limit the exposure to GFT505. Three cohorts of 12 subjects are planned to be included. This part will be run in overweight or obese subjects.
  • Study Part IV will follow the same design and same treatment schedule than Study Part III but will be performed in the target population, patients with Type 2 diabetes and only one dose will be tested in study part IV.
03

Conditions studied

  • Type 2 Diabetes
  • Diabetes Mellitus, Type 2
  • Metabolic Diseases
  • Cardiovascular Diseases
  • Obese
  • Dyslipidemia
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part I :

  • Male or female healthy volunteers 18 to 45 years of age (inclusive).
  • Subjects with a (BMI) ≥ 18 and ≤ 28 kg/m2 at screening.
  • For female subjects of , use of double method.
  • Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not by the principal Investigator.

Part II and III :

  • Male healthy volunteers 18 to 55 years of age (inclusive).
  • Subjects with a BMI >28 and \<35 kg/m2 at screening.
  • Normal arterial BP and pulse rate or, if abnormal, considered not clinically significant by the principal Investigator.

Part IV :

  • Male or female Type 2 diabetic patients 18 to 60 years of age.
  • Females participating in the study must be either of non-child bearing potential or using an efficient double contraception.
  • Currently treated with any antidiabetic treatment (a maximum of two anti-diabetic drugs including metformin in all cases) with the exception of insulin or GLP analogs and agonists therapy.
  • Stable diabetes with glycosylated () \< or =10% or less.
  • Normal renal function as defined by a creatine clearance >90 mL/min calculated with the formula.
  • Subjects with a BMI from 18 to 32 kg/m2 at screening.

Exclusion criteria

Exclusion Criteria:

Part I :

  • Who previously received GFT505.
  • With any abnormality following review of prestudy laboratory tests (Aspartate and must be within normal ranges), vital signs, full physical examination and .
  • Who have a positive laboratory test for surface antigen (HbsAg), or anti- 1/2 (Human immunodeficiency virus) or anti- (Hepatitis C virus) antibodies.
  • Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per week, one unit = 8 g or about 10 mL of pure alcohol).
  • Who drink more than 8 cups daily of beverage containing caffeine.
  • Who have a positive laboratory test for urine drug screening (opiates, cocaine, amphetamine, cannabis, benzodiazepines).
  • Who have undergone surgery or have donated blood within 12 weeks prior to the start of the study.
  • Who have taken any prescribed or over the counter drug (including antacid drug), with the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first dose administration.

Part II and III : specific additional exclusion criteria

  • Who have taken fibrates within 6 weeks prior to the first dose administration.

Part IV : specific additional exclusion criteria

  • With unstable proliferative retinopathy, macular oedema (fundus examination performed in the previous year will be considered relevant on Investigator's judgement).
  • Who have taken fibrates within 6 weeks prior to the first dose administration.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
96 participants (actual)

Study arms

  • Placebo comparator
    Matching placebo

    Drug: Placebo

  • Active comparator
    GFT505 20mg - old formulation

    Study Part I : dose level = 120mg

    Drug: GFT505 120mg - old formulation

  • Experimental
    GFT505 60mg - new formulation

    Study Part I : dose level = 120mg ; Study Part II : dose level = 180mg, 240mg and 300mg ; Study Part III : dose level = 120mg, 180mg and 240mg ; Study Part IV : dose level = 120mg or 180mg.

    Drug: GFT505 120mg - new formulation · Drug: GFT505 180mg - new formulation · Drug: GFT505 240mg - new formulation · Drug: GFT505 300mg - new formulation

Interventions

  • hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.

  • hard gelatin capsules dosed at 60mg, one single oral administration (Study Part I) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 2 capsules with 250mL of water.

  • hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.

  • hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.

  • hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II), 5 capsules with 250mL of water.

  • DrugPlacebo

    hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics parameters (Study Part I)

    For each subject at each Treatment Period, blood will be collected at the following time points: pre-dose, and 0.5, 1, 1.5, 2, 4, 6, 8, 12 and 24 h post-dose.

    Time frame: 24h post-dose

  2. Safety parameters (Study Parts II, III and IV)

    Monitoring for the occurrence of AEs. Changes in physical examination, vital signs (blood pressure and pulse rate), ECG, and clinical laboratory tests (biochemistry, hematology, and urinalysis).

    Time frame: Part II : 5 days ; Part III : 20 days ; Part IV : 20 days

Secondary outcomes

  1. Safety parameters (Study Part I)

    Monitoring for the occurrence of AEs. Changes in physical examination, vital signs (blood pressure and pulse rate), ECG, and clinical laboratory tests (biochemistry, hematology, and urinalysis).

    Time frame: 12 days for male and 5 days for female

  2. Pharmacokinetics parameters (Study Parts II, III and IV)

    Study Part II : For each subject of each dose level, blood will be collected at the following time points: pre-dose, and 0.5, 1, 1.5, 2, 4, 6, 8, 12 and 24 h post-dose. Study Part III and Study Part IV : Assuming a once daily administration, blood will be collected at the following time points: * Day 1 pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 h post-dose. * Days 3, 7, 10, 11, 12 and 13 pre-dose. * Day 14 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 h post-dose.

    Time frame: Part II : 24h post-dose ; Part III : 15 days ; Part IV : 15 days

07

Study locations

1 site
  • SGS Aster S.A.S. - Phase I Clinical Unit
    Paris, 75015, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2011
First posted
Nov 18, 2011
Start
Nov 2011
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Last update
Nov 27, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01474161
Lead sponsor
Genfit
Collaborators
SGS Aster S.A.S., Naturalpha
Responsible party
Sponsor
First posted
Nov 18, 2011
Start date
Nov 2011
Primary completion
Nov 2012
Completion
Nov 2012
Last update
Nov 27, 2012

Study contacts

Rémy Hanf, Development Director
study director · GENFIT, France
Philippe Betting, MD
principal investigator · SGS Aster S.A.S., Phase I Clinical Unit, France

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elifibranor

Start the discussion